This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Microdosing can provide a bit of a safety net if the experience is different than we had imagined but this still doesn’t give us control over the actual direction of the effects. An innovative company called Lucid Mood is using cannabis terpenes to change that and may redefine the trajectory of the marijuana industry in the process.
Happily, the body of research into cannabis and psychedelics (including MDMA) is expanding fast, and it’s likely that better data on their interactions will become available in the near future. The clues we have from existing literature indicate that while it’s probably safe, there’s insufficient clinical research to confirm or dispel it.
We find out how women and other estrogen-predominant people react differently to cannabis than men and those with more testosterone, and why microdosing is far more effective for the former. That’s always the struggle we have when people want data and research and medical research to establish exactly how something works.
Paul is the author of the book Microdosing Psychedelics: A Practical Guide to Upgrade Your Life and the founder and CEO of Third Wave and co-founder of Synthesis. Graham contributes to Psilocybin Alpha as editor-at-large, providing data for patent trackers and writing about IP in the psychedelics space. in/ronanlevy/. The Third Wave.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content